In the biotech news, ConocoPhillips' (COP) potential Permian asset sale valued at $2 billion finds itself under scrutiny. Nevertheless, several firms have shown interest in COP shares: Wealthedge Investment Advisors procured 11,373 shares while DNB Asset Management and Fiera Capital Corp boosted their COP stakes. However, sales were reported by Xponance Inc., TD Asset Management, US Bancorp DE, and Aberdeen Group plc. Notably, the company's valuation and share price momentum were a topic of discussion on Wall Street, with opinions from analysts being mixed.
The company hopes to improve its financial outlook through a programme of cost cuts, scheduled for 2026. However, not all of COP's plans have gathered positive reactions. JP Morgan downgraded COP's position while Roth Capital set a higher target in light of progress on cost cuts. Moreover, analysts anticipate a drop in the company's earnings. Despite market slips, the company’s stock has shown improvement. Yet, some analysts, including those from UBS and Bernstein, have shown caution regarding COP's fiscal health.
Conocophillips COP News Analytics from Wed, 03 Sep 2025 07:00:00 GMT to Sat, 28 Feb 2026 14:15:41 GMT - Rating 4 - Innovation 0 - Information 5 - Rumor -3
